A Phase 1, Single-Dose, Open-Label Study to Characterize and Compare the Pharmacokinetics, Safety, and Effect on QTc Interval of AG-348 in Healthy Subjects of Japanese Origin and Healthy Subjects of Non-Asian Origin

Agios Pharmaceuticals, Inc.1 site in 1 country60 target enrollmentAugust 9, 2017

ConditionsHealthy Japanese Non-Asian

InterventionsAG-348

DrugsAG-348

Overview

Phase: Phase 1
Intervention: AG-348
Conditions: Healthy
Sponsor: Agios Pharmaceuticals, Inc.
Enrollment: 60
Locations: 1
Primary Endpoint: AUC
Status: Completed
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this Phase I, single-dose, open-label trial is to evaluate the pharmacokinetics, safety, and effect on QTc interval of AG-348 in healthy, adult Japanese and Non-Asian subjects. The study plans to evaluate 3 cohorts of a single oral dose of AG-348 in Japanese and Non-Asian subjects. Pharmacokinetic sampling will take place serially at specified times during conduct of the study.

Registry

clinicaltrials.gov

Start Date

August 9, 2017

End Date

October 9, 2017

Last Updated

8 years ago

Study Type

Interventional

Study Design

Sequential

Sex

All

Investigators

Sponsor

Agios Pharmaceuticals, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Be a male or female aged 18 to 55 years, inclusive.
•Have a body mass index (BMI) of ≥ 18.5 to ≤ 29.0 kg/m2 at Screening.
•Be healthy overall with no clinically significant medical abnormalities, as determined by the Investigator through evaluation of the subject's medical history and Screening vital signs, ECG, physical examination, and laboratory assessments.
•Applicable to Japanese Subjects Only: Japanese subjects must have been born in Japan, have both parents and all grandparents of Japanese origin, and not have lived outside of Japan for more than 5 years with no significant changes in lifestyle, including diet, since leaving Japan.
•Applicable to Non-Asian Subjects Only: Non-Asian subjects must have both parents and all grandparents of Non-Asian origin.

Exclusion Criteria

•Have undergone any major surgical procedure within the 3 months prior to Screening.
•Test positive at Screening for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCVAb), or human immunodeficiency virus (HIV).
•Have a Screening systolic blood pressure (BP) reading of \> 140 mmHg (\> 150 mmHg in subjects \> 45 years of age) OR a diastolic BP reading of \> 90 mmHg after 5 minutes of supine rest.
•Have any of the following cardiac risk factors:
•Be taking any medication with a known effect of QT interval prolongation (see list of medications in Appendix 1)
•Have a cardiac pacemaker
•Demonstrate on either the Screening ECG or the baseline ECG any evidence of atrial fibrillation, atrial flutter, complete right or left bundle branch block, or Wolff-Parkinson-White syndrome
•Demonstrate on the Screening ECG any morphology that renders measurement of QT interval imprecise (eg, neuromuscular artifact that cannot be readily eliminated, indistinct QRS onset, low-amplitude T wave, merged T and U waves, prominent U waves, arrhythmia)
•Have a history of a known risk factor for Torsade de Pointes, including any of the following:
•Personal or family history of congenital long QT syndrome, Brugada syndrome, or sudden death

Arms & Interventions

Cohort A

Intervention: AG-348

Cohort B

Intervention: AG-348

Cohort C

Intervention: AG-348

Outcomes

Primary Outcomes

AUC

Time Frame: Pharmacokinetic sampling for AG-348 will be taken for 72 hours (4 days) after single dose

AG-348 Area Under the Curve

Cmax

Time Frame: Pharmacokinetic sampling for AG-348 will be taken for 72 hours (4 days) after single dose

AG-348 Maximum Plasma Concentration

Secondary Outcomes

Incidence of Adverse Events(10 (± 1) days after single-dose of AG-348)
QTc interval(Change in QTc from baseline will be presented by race and by cohort)